Valsartan Dispersible Tablets

The activator of the renin-angiotensin-aldosterone system (RAAS) is angiotensin II, which is formed by angiotensin I under the action of angiotensin converting enzyme (ACE). Angiotensin II binds to specific receptors on the cell membranes of various tissues. It has a variety of physiological effects, including direct or indirect participation in blood pressure regulation. Angiotensin II is a powerful vasoconstrictor with a direct pressor effect. It can also promote sodium reabsorption and stimulate aldosterone secretion. Valsartan Dispersible Tablets Valsartan is an orally effective specific angiotensin (AT) II receptor antagonist that selectively acts on the AT1 receptor subtype and produces all known effects. The AT2 receptor subtype is not related to cardiovascular effects. Valsartan has no partial agonist activity on the AT1 receptor. The affinity of valsartan to the AT1 receptor is 20,000 times stronger than that of the AT2 receptor. ACE converts angiotensin I to angiotensin II and degrades bradykinin. Angiotensin II receptor antagonist - valsartan has no inhibitory effect on ACE, does not cause retention of bradykinin or substance P, and therefore does not cause cough. Clinical trials comparing valsartan with ACE inhibitors have confirmed that the incidence of dry cough in the valsartan group (2.6%) was significantly lower than that in the ACE inhibitor group (7.9%) (P<0.05). In a clinical trial of patients who had developed dry cough symptoms after receiving ACE inhibitor treatment, 19.5%, 19.0%, and 68.5% of patients in the valsartan group, diuretic group, and ACEI group experienced cough, respectively (P<0.05). Valsartan has no effect on other hormone receptors or ion channels known to play an important role in cardiovascular regulation.

Valsartan

This product is white tablets.

Used to treat mild to moderate essential hypertension.

Recommended dose: 80 mg of this product, once a day. The dose has nothing to do with race, age, and gender. It can be taken with meals or on an empty stomach (see absorption). It is recommended to take the medicine at the same time every day (such as in the morning). The exact antihypertensive effect is achieved within 2 weeks of medication, and the maximum therapeutic effect is achieved after 4 weeks. If the antihypertensive effect is not satisfactory, the daily dose can be increased to 160 mg, or a diuretic can be added. Patients with renal insufficiency (severe renal failure is contraindicated) and non-biliary, non-choledostatic liver insufficiency do not need to adjust the dose. Valsartan can be used in combination with other antihypertensive drugs.

Angioneurotic edema, rash, itching and other hypersensitivity reactions such as serum sickness, vasculitis and other allergic reactions. Occasionally, liver function indexes are elevated. Other adverse reactions with an incidence rate of less than 1% include: edema, weakness, insomnia, rash, and decreased libido. Patients with essential hypertension do not need to monitor special laboratory indicators when receiving valsartan treatment.

Allergic to any ingredient: Pregnancy (pregnancy and lactation); There is no experience in using this product in patients with severe renal failure (creatinine clearance <10 ml/min).

Precautions for children: There are no studies on the efficacy and safety of this product for children. There is no experience of using this product for children. Precautions for pregnancy and lactation: Early (first 3 months of pregnancy): pregnancy category B. Animal experiments show no harm to the fetus. Mid- and late (second and third trimesters of pregnancy): pregnancy category D. There is evidence that it is harmful to the human fetus, but the benefits outweigh the risks relative to the therapeutic benefits obtained by the mother. In view of the mechanism of action of angiotensin II receptor antagonists, harm to the fetus cannot be ruled out. The use of drugs that directly act on RAAS in mid- and late pregnancy can cause fetal injury or death. The fetus begins to have renal perfusion from the second trimester, which depends on the development of the RAAS system, so the risk of using this product in mid- and late pregnancy increases. Similar to other drugs that directly act on RAAS, this product should not be used during pregnancy. If pregnancy is discovered during medication, valsartan should be discontinued as soon as possible. All newborns who have been exposed to the drug in utero should be closely observed to ensure adequate urine output, prevent hyperkalemia, and monitor blood pressure. If necessary, appropriate treatment measures (such as rehydration) should be used to remove the drug. Valsartan can be excreted from rabbit milk, but there is no research on lactating women, so this product should not be used during lactation. Precautions for the elderly: Although the systemic exposure concentration of the elderly is slightly higher than that of young people after taking valsartan, it has no clinical significance.

No obvious drug interactions have been found clinically. The following drugs have been studied: cimetidine, warfarin, furosemide, digoxin, atenolol, indomethacin, hydrochlorothiazide, amlodipine and glibenclamide. Since valsartan is almost not metabolized, no clinical interactions with drugs that induce valsartan dispersible tablets or inhibit the cytochrome P450 system have been found. Although valsartan is mostly bound to plasma proteins, in vitro experiments have not found that it interacts with other plasma protein-bound drugs (such as diclofenac, furosemide, and warfarin) at this level. When used in combination with potassium-sparing diuretics (such as spironolactone, triamterene, and amiloride), potassium supplementation or the use of potassium-containing preparations can lead to increased blood potassium concentrations. Therefore, caution is required when using combined medications.

Sealed and moisture-proof

80mg

18 months

Harbin Medisan Pharmaceutical Co., Ltd.

• Founded in:

  1996-06-21

• Address:

  Beijing Road, Limin Development Zone, Harbin

• Tax NO.:

  91230100607168790X

• Registered Funds:

  316.35755 million yuan

• Website:

  Log in to view

• Email:

  Log in to view